FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma

Share this content:
FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma
FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma

WEDNESDAY, Aug. 8, 2018 (HealthDay News) -- Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two rare types of non-Hodgkin lymphoma.

The drug was approved to treat relapsed or refractory mycosis fungoides (MF) and Sézary syndrome (SS) after the patient has had at least one prior therapy delivered through the bloodstream. This application received priority review by the FDA and was approved under the designations of breakthrough therapy and orphan drug.

Poteligeo's approval was based on a clinical trial involving 372 people with relapsed MF or SS, who were given either Poteligeo or the chemotherapy drug vorinostat. Progression-free survival averaged 7.6 months for those who took Poteligeo, versus 3.1 months among those who took vorinostat, the agency said.

Poteligeo's most common side effects included rash, injection-site reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection. More serious side effects could include dermatologic toxicity, infusion reactions, autoimmune problems, and infections, the FDA said.

"Mycosis fungoides and Sézary syndrome are rare, hard-to-treat types of non-Hodgkin lymphoma and this approval fills an unmet medical need for these patients," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, said in a statement.

The drug is produced by the Japanese drugmaker Kyowa Kirin Inc.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes

Study Provides Estimates of U.S. Prevalence of Type ...

Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults

Black Individuals at Highest Risk of Legal Intervention Injury

Black Individuals at Highest Risk of Legal Intervention ...

Increase in rates of injuries from 2005 to 2009, followed by a drop to 2015, returning to ~2005 levels

Research Links Doctor Burnout to Patient Safety Incidents

Research Links Doctor Burnout to Patient Safety Incidents

Physician burnout linked to increased risk of patient safety incidents, reduced patient satisfaction

is free, fast, and customized just for you!




Already a member?

Sign In Now »